https://rasayely-journals.com/index.php/hpbci <p>HPB Cancer International (HPBCI) is an open-access peer-reviewed journal committed to publishing research papers, review articles, clinical studies, case reports, and short communications on the epidemiology, diagnosis, prognosis, and management of cancers in the hepatobiliary or pancreatic system.</p> <p>HPBCI aims to publish high-quality publications by applying a thorough and accurate editorial workflow. The editorial workflow is managed by the editorial board which contains a panel of experts in Hepato-Pancreato-Biliary Cancers.</p> Rasayely en-US HPB Cancer International 2974-3249 <p>Authors retain the copyright of their manuscripts, and all Open Access articles are distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" rel="noopener">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.</p> https://rasayely-journals.com/index.php/hpbci/article/view/72 <p>Cystic neoplasms of the pancreas are a group of pathologies ranging from benign to malignant lesions. Mucinous cystic neoplasm (MCN) of the pancreas comprises rare cysts with malignant potential that typically occur in the body or tail of the pancreas in perimenopausal women. We report a case of an MCN in a patient with complaints of weight loss and dyspeptic symptoms, as this is the first case report in the literature of MCN with a history of previous emergency splenectomy due to blunt trauma.</p> Diego A.G. da Silva Ana V.B. de Amorim Olga L.L. Veloso Sara P.G. Torreão Mariana G. Silveira Péricles J.C. de Oliveira José P.W. Ramalho Copyright (c) 2023 Diego A.G. da Silva, Ana V.B. de Amorim, Olga L.L. Veloso, Sara P.G. Torreão, Mariana G. Silveira, Péricles J.C. de Oliveira, José P.W. Ramalho https://creativecommons.org/licenses/by/4.0 2023-07-15 2023-07-15 1 1 27–29 27–29 https://rasayely-journals.com/index.php/hpbci/article/view/62 <p style="font-weight: 400;"><strong>Introduction:</strong> Liver stiffness measurement (LSM) by transient elastography is associated with risks of HCC and post-surgical outcomes of patients undergoing hepatectomy. However, the role of LSM in patients with advanced HCC is less clear. <strong>Methods:</strong> Patients with a confirmed diagnosis of HCC were prospectively recruited from March 2013 to April 2019. Prior to commencing treatment for HCC, all patients underwent transient elastography (FibroScan®) by hepatologists. The LSM reading, baseline characteristics, and tumor information of patients were recorded. All patients were followed up prospectively for survival events. <strong>Results:</strong> A total of 165 patients with HCC were recruited. The median follow-up was 40.6 months. The median overall survival was 11.9 months. The median age was 62 years with 77% having chronic hepatitis B. Most patients (69.7%) underwent non-surgical treatment (including transarterial chemoembolization and systemic therapy) and supportive care (19.4%) whereas the remaining patients (10.9%) underwent surgery. The median LSM was 26.3kPa (Range = 3.5-75), where the closest integral of 30kPa was chosen as a cut-off for analyses. LSM was correlated with the diameter of the right lobe tumor (R = 0.463; <em>p</em> &lt; 0.0001). It was also correlated with a more advanced BCLC stage (<em>p</em> = 0.0006) and worse ALBI grade (<em>p</em> = 0.0002). Patients with LSM &gt; 30kPa had worse OS than patients with LSM ≤ 30kPa (Median OS = 5.4 months, 95% CI [2.7-8.1] [&gt;30kPa] vs 21.2 months, 95% CI [17.6-24.7] [≤30kPa]; HR = 2.156; [95% Cl = 1.514-3.069]; <em>p</em> = 0.0001). In multivariable analysis, LSM &gt; 30kPa remained an independent predictor of survival after adjustment with ALBI grade, ALP, and BCLC stage. <strong>Discussions:</strong> An LSM &gt;30kPa is a significant and independent predictor of survival for HCC.</p> Ka H. Ngai Grace L.H. Wong Leung Li Frankie Mo Yat M. Lau Kelvin K.C. Ng Terry C.F. Yip Vincent W.S. Wong Henry L.Y. Chan Stephen L. Chan Copyright (c) 2023 Ka H. Ngai, Grace L.H. Wong, Leung Li, Frankie Mo, Yat M. Lau, Kelvin K.C. Ng, Terry C.F. Yip, Vincent W.S. Wong, Henry L.Y. Chan, Stephen L. Chan https://creativecommons.org/licenses/by/4.0 2023-07-15 2023-07-15 1 1 19–26 19–26 https://rasayely-journals.com/index.php/hpbci/article/view/55 <p>Pancreatic neuroendocrine tumors (pNETs) are rare, heterogeneous malignancies with varied presentation and management. PNETs are categorized into syndromic and non-syndromic based on clinical manifestations secondary to the secretion of bioactive peptides. Approximately 10% of pNETs are associated with an inherited syndrome with an established genetic predisposition to tumor development. Generic non-invasive biomarker testing can be utilized for monitoring disease progression and treatment response, but these are non-specific and may be falsely elevated due to various factors. Non-invasive imaging modalities are effective methods of localization, but angiography, endoscopic ultrasound, and intraoperative palpation with ultrasound are beneficial adjuncts for localization. Overall survival and prognosis vary considerably based on tumor pathology, differentiation, and proliferation index, but many malignant tumors are clinically silent and are recognized after locoregional or metastatic spread. Surgical resection with negative margins can be curative for tumors identified at an early stage. For unresectable or metastatic disease, locoregional therapy and systemic treatment are options. In this review, we discuss the clinical presentation, diagnosis, and potential management options of pNETs. </p> Leva Gorji Asfar S. Azmi Najeeb Al Hallak Eliza W. Beal Copyright (c) 2023 Leva Gorji, Asfar S. Azmi, Najeeb Al Hallak, Eliza W. Beal https://creativecommons.org/licenses/by/4.0 2023-07-15 2023-07-15 1 1 4–18 4–18 https://rasayely-journals.com/index.php/hpbci/article/view/56 Maple Ye Feng Stephen Lam Chan Copyright (c) 2023 Maple Ye Feng, Stephen Lam Chan https://creativecommons.org/licenses/by/4.0 2023-07-15 2023-07-15 1 1 1–3 1–3